<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00096278</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-03017</org_study_id>
    <secondary_id>NSABP-C-08</secondary_id>
    <secondary_id>U10CA012027</secondary_id>
    <nct_id>NCT00096278</nct_id>
  </id_info>
  <brief_title>Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer</brief_title>
  <official_title>A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma of the Colon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase III trial is studying giving oxaliplatin, leucovorin, and fluorouracil
      together with bevacizumab to see how well it works compared to oxaliplatin, leucovorin, and
      fluorouracil alone in treating patients who have undergone surgery for stage II or stage III
      colon cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil,
      work in different ways to stop tumor cells from dividing so they stop growing or die.
      Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or
      deliver tumor-killing substances to them without harming normal cells. Bevacizumab may also
      stop the growth of tumor cells by stopping blood flow to the tumor. Giving chemotherapy
      together with bevacizumab may kill more tumor cells. It is not yet known whether treatment
      with oxaliplatin, leucovorin, and fluorouracil is more effective with or without bevacizumab
      in treating patients who have undergone surgery for colon cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare the relative efficacy of mFOLFOX6 + bevacizumab with that of mFOLFOX6 alone in
      prolonging disease-free survival (DFS).

      SECONDARY OBJECTIVES:

      I. To compare the relative efficacy of mFOLFOX6 + bevacizumab with that of mFOLFOX6 alone in
      prolonging survival (S).

      TERTIARY OBJECTIVES:

      I. To assess the persistence of proteinuria following the discontinuation of bevacizumab.

      II. To correlate the development of proteinuria with clinical sequelae. III. To evaluate the
      risk factors for development of proteinuria. IV. To determine the effect of discontinuation
      of bevacizumab on hypertension. V. To estimate the incidence of delayed vascular events such
      as myocardia infarction, CNS ischemia, and thrombosis in patients receiving chemotherapy +
      bevacizumab.

      VI. To assess the effect of bevacizumab on ovarian function in premenopausal women.

      VII. To assess the incidence rate of immunogenicity and examine post-treatment serum levels
      of bevacizumab in patients receiving bevacizumab.

      OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment
      arms.

      ARM I: Patients receive adjuvant chemotherapy comprising concurrent oxaliplatin and
      leucovorin calcium IV over 2 hours on day 1. Patients also receive adjuvant fluorouracil IV
      over 2-4 minutes on day 1 followed by fluorouracil IV continuously over 46 hours on days 1
      and 2. Treatment repeats every 14 days for 12 courses in the absence of disease progression
      or unacceptable toxicity.

      ARM II: Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive
      adjuvant oxaliplatin, leucovorin calcium, and fluorouracil as in arm I. Treatment repeats
      every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.
      After completion of adjuvant chemotherapy, patients continue to receive bevacizumab alone
      every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.

      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
      annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Where events are defined as recurrence, second primary cancer, or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival as Assessed by Death From Any Cause</measure>
    <time_frame>Every 6 months for 4 years and then every 12 months until death from any cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria After Completion of Bevacizumab</measure>
    <time_frame>For Groups 1 and 2 at the end of every 3 cycles of chemotherapy plus or minus bevacizumab; for Group 2 patients, every 6 weeks for 6 months. If UPC ratio is greater than or equal to 1.0 at the end of therapy then test every 3 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria With Clinical Sequelae</measure>
    <time_frame>For Groups 1 and 2 at the end of every 3 cycles of chemotherapy plus or minus bevacizumab; for Group 2 patients, every 6 weeks for 6 months. If UPC ratio is greater than or equal to 1.0 at the end of therapy then test every 3 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Risk Factors for Development of Proteinuria</measure>
    <time_frame>For Groups 1 and 2 at the end of every 3 cycles of chemotherapy plus or minus bevacizumab; for Group 2 patients, every 6 weeks for 6 months. If UPC ratio is greater than or equal to 1.0 at the end of therapy then test every 3 months for 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>As Measured by Blood Pressure and Antihypertensive Medication Hypertension</measure>
    <time_frame>Group 2, every 3 months for one year post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed Vascular Events Such as Myocardial Infarction, Central Nervous System (CNS) Ischemia, and Thrombosis in Patients Receiving Chemotherapy + Bevacizumab</measure>
    <time_frame>Events measured regularly during chemotherapy and bevacizumab therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ovarian Function in Premenopausal Women as Measured by Serum Ovarian Function Test</measure>
    <time_frame>Group 2: Measured pre-therapy and then every 6 months for 2 years following randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bevacizumab Immunogenicity and Post-treatment Serum Levels of Bevacizumab in Patients Receiving Bevacizumab</measure>
    <time_frame>Group 2: Pre-therapy, every 2 weeks during chemotherapy/bevacizumab therapy, every 6 weeks during bevacizumab therapy and at 3 and 6 months after completion of bevacizumab therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2710</enrollment>
  <condition>Adenocarcinoma of the Colon</condition>
  <condition>Stage IIA Colon Cancer</condition>
  <condition>Stage IIB Colon Cancer</condition>
  <condition>Stage IIC Colon Cancer</condition>
  <condition>Stage IIIA Colon Cancer</condition>
  <condition>Stage IIIB Colon Cancer</condition>
  <condition>Stage IIIC Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I (mFOLFOX6)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive adjuvant chemotherapy comprising concurrent oxaliplatin and leucovorin calcium IV over 2 hours on day 1. Patients also receive adjuvant fluorouracil IV over 2-4 minutes on day 1 followed by fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (bevacizumab, mFOLFOX6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab IV over 30-90 minutes on day 1. Patients also receive adjuvant oxaliplatin, leucovorin calcium, and fluorouracil as in arm I. Treatment repeats every 14 days for 12 courses in the absence of disease progression or unacceptable toxicity. After completion of adjuvant chemotherapy, patients continue to receive bevacizumab alone every 14 days for 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (mFOLFOX6)</arm_group_label>
    <arm_group_label>Arm II (bevacizumab, mFOLFOX6)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin calcium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (mFOLFOX6)</arm_group_label>
    <arm_group_label>Arm II (bevacizumab, mFOLFOX6)</arm_group_label>
    <other_name>CF</other_name>
    <other_name>CFR</other_name>
    <other_name>LV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (mFOLFOX6)</arm_group_label>
    <arm_group_label>Arm II (bevacizumab, mFOLFOX6)</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II (bevacizumab, mFOLFOX6)</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must consent to be in the study and must have signed and dated an IRB
             approved consent form conforming to federal and institutional guidelines

          -  Randomization must occur during the three-week interval beginning on postoperative day
             29 and ending on postoperative day 50

          -  The distal extent of the tumor must be &gt;= 12 cm from the anal verge on endoscopy; if
             the patient is not a candidate for endoscopy, then the distal extent of the tumor must
             be &gt;= 12 cm from the anal verge as determined by surgical examination

          -  The patient must have had an en bloc complete gross resection of tumor (curative
             resection) by open laparotomy or laparoscopically-assisted colectomy; patients who
             have had a two-stage surgical procedure, to first provide a decompressive colostomy
             and then in a later procedure to have the definitive surgical resection, are eligible

          -  Patients must have histologically confirmed adenocarcinoma of the colon that meets one
             of the criteria below:

               -  Stage II carcinoma (T3,4 N0 M0); the tumor invades through the muscularis propria
                  into the subserosa or into non-peritonealized pericolic or perirectal tissues
                  (T3); or directly invades other organs or structures, and/or perforates visceral
                  peritoneum (T4)

               -  Stage III carcinoma (any T N1,2 M0); the tumor has invaded to any depth, with
                  involvement of regional lymph nodes

          -  Patients with T4 tumors that have involved an adjacent structure (e.g., bladder, small
             intestine, ovary, etc.) by direct extension from the primary tumor are eligible if all
             of the following conditions are met:

               -  All or a portion of the adjacent structure was removed en bloc with the primary
                  tumor

               -  In the opinion of the surgeon, all grossly visible tumor was completely resected
                  (&quot;curative resection&quot;)

               -  Histologic evaluation by the pathologist confirms the margins of the resected
                  specimen are not involved by malignant cells; and

               -  Local radiation therapy will not be utilized

          -  Patients with more than one synchronous primary colon tumor are eligible; (staging
             classification will be based on the more advanced primary tumor)

          -  Patients must have an ECOG performance status of 0 or 1

          -  At the time of randomization, postoperative absolute granulocyte count (AGC) must be
             &gt;= 1500/mm^3 (or &lt; 1500/mm^3, if in the opinion of the investigator, this represents
             an ethnic or racial variation of normal)

          -  At the time of randomization, the postoperative platelet count must be &gt;= 100,000/mm^3

          -  Bilirubin must be =&lt; ULN for the lab unless the patient has a chronic grade 1
             bilirubin elevation due to Gilbert's disease or similar syndrome due to slow
             conjugation of bilirubin

          -  Alkaline phosphatase must be &lt; 2.5 x ULN for the lab

          -  AST must be &lt; 1.5 x ULN for the lab

               -  If AST is &gt; ULN, serologic testing for hepatitis B and C must be performed and
                  results must be negative

          -  Serum creatinine =&lt; 1.5 x ULN for the lab

          -  Urine protein/creatinine (UPC) ratio of &lt; 1.0; patients with a UPC ratio &gt;= 1.0 must
             undergo a 24-hour urine collection, which must be an adequate collection and must
             demonstrate &lt; 1 gm of protein in the 24-hour urine collection in order to participate
             in the study

          -  Patients with prior malignancies, including colorectal cancers, are eligible if they
             have been disease-free for &gt;= 5 years and are deemed by their physician to be at low
             risk for recurrence; patients with squamous or basal cell carcinoma of the skin,
             melanoma in situ, carcinoma in situ of the cervix, or carcinoma in situ of the colon
             or rectum that have been effectively treated are eligible, even if these conditions
             were diagnosed within 5 years prior to randomization

        Exclusion Criteria:

          -  Patients &lt; 18 years old

          -  Colon tumor other than adenocarcinoma, i.e., sarcoma, lymphoma, carcinoid, etc

          -  Rectal tumors, i.e. a tumor located &lt; 12 cm from the anal verge on endoscopy, or by
             surgical exam if the patient is not a candidate for endoscopy

          -  Isolated, distant, or non-contiguous intra-abdominal metastases, even if resected

          -  Any systemic or radiation therapy initiated for this malignancy

          -  Any significant bleeding that is not related to the primary colon tumor within 6
             months before study entry

          -  Serious or non-healing wound, skin ulcers, or bone fracture

          -  Gastroduodenal ulcer(s) determined by endoscopy to be active

          -  Invasive procedures defined as follows:

               -  Major surgical procedure, open biopsy, or significant traumatic injury within 28
                  days prior to randomization

               -  Anticipation of need for major surgical procedures during the course of the study

               -  Core biopsy or other minor procedure, excluding placement of a vascular access
                  device, within 7 days prior to randomization

          -  Uncontrolled blood pressure defined as &gt; 150/90 mmHg

          -  History of TIA or CVA

          -  History of arterial thrombotic event within 12 months before study entry

          -  Symptomatic peripheral vascular disease

          -  PT/INR &gt; 1.5, unless the patient is on therapeutic doses of warfarin. If so, the
             following criteria must be met for enrollment:

               -  The subject must have an in-range INR (usually between 2 and 3) on a stable dose
                  of warfarin

               -  The subject must not have active bleeding or a pathological condition that is
                  associated with a high-risk of bleeding

          -  Concomitant halogenated antiviral agents

          -  Clinically significant peripheral neuropathy at the time of randomization (defined in
             the NCI Common Terminology Criteria for Adverse Events Version 3.0 [CTCAE v3.0] as
             grade 2 or greater neurosensory or neuromotor toxicity)

          -  Non-malignant systemic disease (cardiovascular, renal, hepatic, etc.) that would
             preclude any of the study therapy drugs; specifically excluded are the following
             cardiac conditions:

               -  New York Heart Association Class III or IV cardiac disease

               -  History of myocardial infarction within 12 months before study entry

               -  Unstable angina within 12 months before study entry; and

               -  Symptomatic arrhythmia

          -  History of chronic or persistent viral hepatitis or other chronic liver disease

          -  Pregnancy or lactation at the time of proposed randomization; eligible patients of
             reproductive potential (both sexes) must agree to use adequate contraceptive methods
             during study therapy and for at least 3 months after the completion of bevacizumab

          -  Psychiatric or addictive disorders or other conditions that, in the opinion of the
             investigator, would preclude the patient from meeting the study requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Allegra</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSABP Foundation Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Surgical Adjuvant Breast and Bowel Project</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212-5234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Ireland</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2004</study_first_submitted>
  <study_first_submitted_qc>November 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2004</study_first_posted>
  <results_first_submitted>October 31, 2012</results_first_submitted>
  <results_first_submitted_qc>November 30, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2012</results_first_posted>
  <last_update_submitted>May 16, 2014</last_update_submitted>
  <last_update_submitted_qc>May 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil</title>
          <description>Oxaliplatin + Leucovorin + 5-Fluorouracil</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab</title>
          <description>Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1356"/>
                <participants group_id="P2" count="1354"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1338"/>
                <participants group_id="P2" count="1334"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No follow-up data</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient not at risk for primary endpoint</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oxaliplatin + Leucovorin + 5-Fluorouracil</title>
          <description>Oxaliplatin + Leucovorin + 5-Fluorouracil</description>
        </group>
        <group group_id="B2">
          <title>Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab</title>
          <description>Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1356"/>
            <count group_id="B2" value="1354"/>
            <count group_id="B3" value="2710"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="11.6"/>
                    <measurement group_id="B2" value="56" spread="11.3"/>
                    <measurement group_id="B3" value="57" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="680"/>
                    <measurement group_id="B2" value="678"/>
                    <measurement group_id="B3" value="1358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="676"/>
                    <measurement group_id="B2" value="676"/>
                    <measurement group_id="B3" value="1352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival</title>
        <description>Where events are defined as recurrence, second primary cancer, or death from any cause</description>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil</title>
            <description>Oxaliplatin + Leucovorin + 5-Fluorouracil</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab</title>
            <description>Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival</title>
          <description>Where events are defined as recurrence, second primary cancer, or death from any cause</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1338"/>
                <count group_id="O2" value="1334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5"/>
                    <measurement group_id="O2" value="77.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival as Assessed by Death From Any Cause</title>
        <time_frame>Every 6 months for 4 years and then every 12 months until death from any cause</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proteinuria After Completion of Bevacizumab</title>
        <time_frame>For Groups 1 and 2 at the end of every 3 cycles of chemotherapy plus or minus bevacizumab; for Group 2 patients, every 6 weeks for 6 months. If UPC ratio is greater than or equal to 1.0 at the end of therapy then test every 3 months for 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proteinuria With Clinical Sequelae</title>
        <time_frame>For Groups 1 and 2 at the end of every 3 cycles of chemotherapy plus or minus bevacizumab; for Group 2 patients, every 6 weeks for 6 months. If UPC ratio is greater than or equal to 1.0 at the end of therapy then test every 3 months for 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Risk Factors for Development of Proteinuria</title>
        <time_frame>For Groups 1 and 2 at the end of every 3 cycles of chemotherapy plus or minus bevacizumab; for Group 2 patients, every 6 weeks for 6 months. If UPC ratio is greater than or equal to 1.0 at the end of therapy then test every 3 months for 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>As Measured by Blood Pressure and Antihypertensive Medication Hypertension</title>
        <time_frame>Group 2, every 3 months for one year post treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Delayed Vascular Events Such as Myocardial Infarction, Central Nervous System (CNS) Ischemia, and Thrombosis in Patients Receiving Chemotherapy + Bevacizumab</title>
        <time_frame>Events measured regularly during chemotherapy and bevacizumab therapy</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ovarian Function in Premenopausal Women as Measured by Serum Ovarian Function Test</title>
        <time_frame>Group 2: Measured pre-therapy and then every 6 months for 2 years following randomization</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bevacizumab Immunogenicity and Post-treatment Serum Levels of Bevacizumab in Patients Receiving Bevacizumab</title>
        <time_frame>Group 2: Pre-therapy, every 2 weeks during chemotherapy/bevacizumab therapy, every 6 weeks during bevacizumab therapy and at 3 and 6 months after completion of bevacizumab therapy</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Participants at Risk includes any patient who submitted an Adverse Event (AE) form.</desc>
      <group_list>
        <group group_id="E1">
          <title>Oxaliplatin + Leucovorin + 5-Fluorouracil</title>
          <description>Oxaliplatin + Leucovorin + 5-Fluorouracil</description>
        </group>
        <group group_id="E2">
          <title>Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab</title>
          <description>Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="270" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>External ear inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Extraocular muscle paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Colonic hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Colonic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Duodenal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Duodenal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Duodenal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Jejunal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Sudden death NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Peritoneal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Pelvic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Scrotal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Small intestine infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Large intestinal anastomotic leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased (ALT/SGPT)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased (AST/SGOT)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Cardiac troponin T increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Pelvic soft tissue necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Scrotal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Uterine hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Visceral arterial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE v4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="954" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="1043" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="128" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="153" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="122" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="433" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="400" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="586" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="660" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="172" subjects_at_risk="1334"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="1326"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="1334"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Division of Regulatory Affairs</name_or_title>
      <organization>NSABP Foundation, Inc.</organization>
      <phone>412-330-4600</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

